Gene therapy restores hearing in rare deafness cases

Gene therapy restores hearing deafness in a groundbreaking study that offers new hope for people born with rare genetic hearing loss.

Researchers say the experimental treatment has shown both safety and lasting effectiveness, marking a major milestone in the field of auditory medicine.

A breakthrough for genetic hearing loss

The study, led by Zheng-Yi Chen and published in Nature, is the largest and longest to date testing gene therapy for deafness.

The results suggest, for the first time, that hearing could be restored in patients who were previously unable to detect any sound.

“This is really a brand-new treatment option,” Chen said, highlighting the significance of the findings.

How the therapy works

The treatment targets a rare genetic condition known as DFNB9, caused by mutations in the OTOF gene.

To address this, scientists used a modified virus to deliver a healthy version of the gene directly into the inner ear. The goal is to restore production of a key protein needed to transmit sound signals to the brain.

In simple terms, the therapy replaces what is missing—allowing the ear to function properly.

Strong and lasting results

The gene therapy restores hearing deafness trial involved 42 patients, ranging from infants to adults.

Around 90% of participants experienced significant improvements. Many began hearing sounds within weeks of treatment, with continued progress over several months.

In some cases, patients achieved near-normal hearing levels. Notably, the benefits have lasted more than two years for several participants.

This durability raises the possibility that the therapy could be a one-time treatment with lifelong effects.

Transforming patients’ lives

The impact goes beyond hearing alone.

Patients who regained hearing were able to begin developing speech, dramatically improving their ability to communicate.

Experts say early intervention is key. Treating patients at a younger age appears to produce the best outcomes, which could lead to expanded screening for genetic deafness in newborns.

A growing field of innovation

The findings align with similar advances from other research groups and companies, including Regeneron Pharmaceuticals, which is developing a comparable therapy that may soon receive regulatory approval.

According to Lawrence Lustig, the ability to restore natural hearing could be a “game changer” for the field.

Researchers are now exploring whether similar approaches could treat other forms of genetic deafness—and potentially even more common hearing loss caused by aging or noise exposure.

Safety and next steps

So far, the treatment appears to be safe. However, scientists emphasize the need for longer follow-up to confirm both safety and durability over time.

Still, the gene therapy restores hearing deafness breakthrough represents a major step forward—bringing the possibility of reversing certain forms of deafness closer to reality.